Experienced in Orbital Pseudotumor

Tomoya Miyamura

Fukuoka, JP 
Experienced in Orbital Pseudotumor
Fukuoka, JP 
OverviewLocationsClinical Research

Overview

Tomoya Miyamura practices in Fukuoka, Japan. Mr. Miyamura is rated as an Experienced expert by MediFind in the treatment of Orbital Pseudotumor. His top areas of expertise are Rheumatoid Lung Disease, Rheumatoid Arthritis (RA), Arthritis, and Systemic Lupus Erythematosus (SLE).

His clinical research consists of co-authoring 48 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Orbital Pseudotumor.

Gender
Male

Locations

Fukuoka, Japan
Other Locations
Tokyo, Japan
Yokohama, Japan
Chuo, 8100065, Japan
Kumamoto, Japan
Meguro, 1528621, Japan
Jigyohama, 8108563, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Adults With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Adults With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: April 23, 2024
Intervention Type: Drug
Study Drug: LY3471851
Study Phase: Phase 2
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: November 23, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
View 2 Less Clinical Trials

48 Total Publications

Nuclear keratin 6A upregulates human papillomavirus oncogene expression through TEAD1 interaction.
Nuclear keratin 6A upregulates human papillomavirus oncogene expression through TEAD1 interaction.
Journal: Virology journal
Published: April 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Miyamura's expertise for a condition
ConditionClose
      View All 21 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile